SCHEMBL25920577

SCHEMBL25920577

O=[N+]([O-])c1cccc(CNc2ccc(O)cc2)c1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.62
ALDH1A1 P00352 5/20 0.62
KDM4E B2RXH2 2/20 0.62
TDP1 Q9NUW8 1/20 0.62
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
L3MBTL1 Q9Y468 2/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TSHR P16473 2/20 0.51
ALOX15 P16050 1/20 0.51
PTPRF P10586 1/20 0.51
PTPN2 P17706 1/20 0.51
PTPN1 P18031 1/20 0.51
PTPN11 Q06124 1/20 0.51
GAA P10253 1/20 0.51
THRB P10828 1/20 0.51
PKM P14618 1/20 0.51
RAB9A P51151 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25920592 0.87 ALDH1A1 (0.61) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL7338580 0.86 PTPRF (0.69) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL30301289 0.85 CYP1A2 (0.65) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL11226242 0.85 MAPT (0.58) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL11250764 0.85 GAA (0.60) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL6154644 0.83 MAPT (0.57) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL13812984 0.83 MAPT (0.62) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL4956305 0.83 PTPRF (0.68) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL17653420 0.82 MAPT (0.66) MAPTALDH1A1KDM4ETDP1MEN1
SCHEMBL3294789 0.80 MAPT (0.57) MAPTALDH1A1KDM4ETDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 MAPT 4492/4885ALDH1A1 2654/4885KDM4E 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.